Enhanced intracellular delivery of the reactive oxygen species (ROS)-generating copper chelator D-penicillamine via a novel gelatin-D-penicillamine conjugate

Bioconjugate Chemistry

Volumn 19, Issue 7, 2008, Pages 1382-1388

  Gupte, Anshul ^a   Wadhwa, Saurabh ^b   Mumper, Russell J ^b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYSIS; CELLS; COPPER; COVALENT BONDS; CYTOLOGY; DISEASES; ENZYME ACTIVITY; OXYGEN; PEPTIDES; SULFUR COMPOUNDS;

ANTI-CANCER AGENTS; CELL UPTAKE; COPPER CATALYZED; GLUTHATHIONE; HUMAN LEUKEMIA CELLS; IN-VIVO; INTRACELLULAR DELIVERY; INTRACELLULAR UPTAKE; REACTIVE OXYGEN SPECIES; SYNTHESISED;

CHELATION;

COPPER; GELATIN; GLUTATHIONE; N SUCCINIMIDYL 3 (2 PYRIDYLTHIO)PROPIONATE; PENICILLAMINE; PROPIONIC ACID DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL STRAIN HL 60; CELL TRANSPORT; CHEMICAL LABELING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; COVALENT BOND; DISULFIDE BOND; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MIXTURE; DRUG RELEASE; DRUG SYNTHESIS; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PH; PHYSICAL CHEMISTRY; QUALITATIVE ANALYSIS;

EID: 47749156009     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800042s     Document Type: Article

References (36)

1. Brem, S., Grossman, S. A., Carson, K. A., New, P., Phuphanich, S., Alavi, J. B., Mikkelsen, T., and Fisher, J. D. (2005) Phase 2 trial of copper depletion and penicillamine as anti-angiogenesis therapy of glioblastoma. Neuro-Oncol. 7, 246-253.
2. Brewer, G. J. (2005) Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Discovery Today 10, 1103-1109.
3. 4. J. Clin. Invest. 65, 1069-1076.
4. Starkebaum, G., and Root, R. K. (1985) D-penicillamine: analysis of the mechanism of copper catalyzed hydrogen peroxide generation. J. Immunol. 134, 3371-3378.
5. Gupte, A., and Mumper, R. J. (2007) An investigation into copper catalyzed D-penicillamine oxidation and subsequent hydrogen peroxide generation. J. Inorg. Biochem. 101, 594-602.
6. Gupte, A., and Mumper, R. J. (2007) Copper chelation by D-penicillamine generates reactive oxygen species that are cytotoxic to human leukemia and breast cancer cells. Free Radical Biol. Med. 43, 1271-1278.
7. Yucel, I., Arpaci, F., Ozet, A., Doner, B., Karayilanoglu, T., Sayar, A., and Berk, O. (1994) Serum copper and zinc and copper/zinc ratio in patients with breast cancer. Biol. Trace Elem. Res. 40, 31-38.
8. Zuo, X. L., Chen, J. M., Zhou, X., Li, X. Z., and Mei, G. Y. (2006) Levels of selenium, zinc, copper and antioxidant enzyme activity in patients with leukemia. Biol. Trace Elem. Res. 114, 41-53.
9. Geraki, K., Farquharson, M. J., and Bradley, D. A. (2002) Concentration of Fe, Cu and Zn in breast tissue: a synchrotron XRF study. Phys. Med. Biol. 47, 2327-2339.
10. Kuo, H. W., Chen, S. F., Wu, C. C., Chen, D. R., and Lee, J. H. (2002) Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol. Trace Elem. Res. 89, 1-11.
11. Sharma, K., Mittal, D. K., Kesarwani, R. C., Kamboj, V. P., and Chowdhery. (1994) Diagnostic and prognostic significance of serum and tissue trace elements in breast malignancy. Ind. J. Med. Sci. 48, 227-232.
12. Chvapil, M., Kielar, F., Liska, F., Silhankova, A., and Brendel, K. (2005) Synthesis and evaluation of long acting D-penicillamine derivatives. Connect. Tissue Res. 46, 242-250.
13. Joyce, D. A. (1989) D-penicillamine pharmacokinetics and pharmacodynamics in man. Pharmac Ther. 42, 405-427.
14. Joyce, D. A. (1990) D-penicillamine. Bailliere's Clin. Rheum. 4, 553-574.
15. Lu, J. X., Jr. (1992) Penicillamine: pharmacokinetics and differential effects on zinc and copper status in chicks. J. Nutr. 122, 355-362.
16. Netter, P., Bannwarth, B., Pere, P., and Nicolas, A. (1987) Clinical pharmacokinetics of D-penicillamine. Clin. Pharmacokinetics 13, 317-333.
17. Cui, Z., Lockman, P. R., Atwood, C. S., Hsu, C-H., Gupte, A., Allen, D. D., and Mumper, R. J. (2005) Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm. 59, 163-111.
18. Chvapil, M., and Dorr, R. (2005) Single intratumoral injection of long acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice. Anti-cancer Drugs 16, 757-762.
19. Bowman, B. J., and Ofner, C. M. III. (2000) Characterization and in-vitro methotrexate release from methotrexate/gelatin conjugates of opposite bond polarity. Pharm. Res. 17, 1309-1315.
20. Ofner, C. M., Pica, K., Bowman, B. J., and Chen, C. S. (2006) Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates. Int. J. Pharm. 308, 90-99.
21. Young, S., Wong, M., Tabata, Y., and Mikos, A. G. (2005) Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J. Controlled Release 109, 256-274.
22. Kommareddy, S., and Amiji, M. (2005) Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjugate Chem. 16, 1423-1432.
23. Bhavsar, M. D., and Amiji, M. M. (2007) Gastrointestinal distribution and in vivo gene transfection studies with nanopar ticles-in-microsphere oral system (NiMOS). J. Controlled Release 119, 339-348.
24. Thakor, D., Spigelman, I., Tabata, Y., and Nishimura, I. (2007) Subcutaneous peripheral injection of cationized gelatin/DNA polyplexes as a platform for non-viral gene transfer to sensory neurons. Mol. Ther. 15, 2124-2131.
25. Xia, Z., Abe, K., Furusu, A., Miyazaki, M., Obata, Y., Tabata, Y., Koji, T., and Kohno, S. (2008) Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heal shock protein 47. Am. J. Nephrol. 28, 34-46.
26. Chung, J. E., Kurisawa, M., Uyama, H., and Kobayashi, S. (2003) Enzymatic synthesis and antioxidant property f gelatin-catechin conjugates. Biotechnol. Lett. 25, 1993-1997.
27. Pica, K., Tchao, R., and Ofner, C. M., III (2006) Gelatin-methotrexate conjugate microspheres as a potential drug delivery system. J. Pharm. Sci. 95, 1896-1908.
28. Azarmi, S., Huang, Y., Chen, H., McQuarrie, S., Abrams, D., Roa, W., Finaly, W. H., Miller, G. G., and Lobenberg, R. (2006) Optimization of a two step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J. Pharm. Pharmaceut. Sci 9, 124-132.
29. Kaul, G., and Amiji, M. (2002) Long circulating poly (ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm. Res. 19, 1061-1067.
30. Kommareddy, S., and Amiji, M. (2007) Biodistribution and pharmacokinetic analysis of long circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J. Pharm. Sci. 96, 391-401.
31. Xu, X., Capita, R. M., and Spector, M. (2008) Delivery of plasmid IGF-1 to chondrocytes via cationized gelatin nanoparticles. J. Biomed Mater. Res. A 84, 73-83.
32. Saito, G., Swanson, J. A., and Lee, K. D. (2003) Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Delivery Rev. 55, 199-215.
33. Schafer, F. Q., and Buettner, G. R. (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radical Biol. Med. 30, 1191-1212.
34. Cavallaro, G., Campisi, M., Licciardi, M., Orgis, M., and Giammona, G. (2006) Reversible stable thiopolyplexes for intracellular delivery of genes. J. Controlled Release 115, 311-334.
35. Jones, D. P., Carlson, J. L., Mody, V. C., Cai, J., Lynn, M. J., and Sternberg, P. (2000) Redox state of glutathione in human plasma. Free Rad. Biol. Med. 28, 625-635.
36. Lodemann, E. (1981) Transport of D- and L-penicillamine by mammalian cells. Biochem. Biophys. Res. Commun. 102, 775-783.